Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Return on Assets (2021 - 2025)

Historic Return on Assets for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to 0.68%.

  • Lyra Therapeutics' Return on Assets rose 4400.0% to 0.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68%, marking a year-over-year increase of 4400.0%. This contributed to the annual value of 0.89% for FY2024, which is 4000.0% down from last year.
  • As of Q3 2025, Lyra Therapeutics' Return on Assets stood at 0.68%, which was up 4400.0% from 0.71% recorded in Q2 2025.
  • In the past 5 years, Lyra Therapeutics' Return on Assets ranged from a high of 0.44% in Q3 2022 and a low of 1.3% during Q1 2025
  • Over the past 5 years, Lyra Therapeutics' median Return on Assets value was 0.63% (recorded in 2023), while the average stood at 0.73%.
  • As far as peak fluctuations go, Lyra Therapeutics' Return on Assets plummeted by -8100bps in 2024, and later soared by 4400bps in 2025.
  • Lyra Therapeutics' Return on Assets (Quarter) stood at 0.71% in 2021, then surged by 32bps to 0.48% in 2022, then increased by 1bps to 0.48% in 2023, then tumbled by -170bps to 1.29% in 2024, then skyrocketed by 47bps to 0.68% in 2025.
  • Its Return on Assets stands at 0.68% for Q3 2025, versus 0.71% for Q2 2025 and 1.3% for Q1 2025.